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Background: Mitochondrial DNA damage, increased production of reactive oxygen species and progressive
respiratory chain dysfunction, together with increased deposition of cholesterol and cholesteryl esters, are hallmarks
of atherosclerosis. This study investigated the role of mitochondrial function in regulation of macrophage
cholesterol efflux to apolipoprotein A-I, by the addition of established pharmacological modulators of
mitochondrial function.
Methods: Murine RAW 264.7 macrophages were treated with a range of concentrations of resveratrol, antimycin,
dinitrophenol, nigericin and oligomycin, and changes in viability, cytotoxicity, membrane potential and ATP,
compared with efflux of [3H]cholesterol to apolipoprotein (apo) A-I. The effect of oligomycin treatment on
expression of genes implicated in macrophage cholesterol homeostasis were determined by quantitative
polymerase chain reaction, and immunoblotting, relative to the housekeeping enzyme, Gapdh, and combined with
studies of this molecule on cholesterol esterification, de novo lipid biosynthesis, and induction of apoptosis.
Significant differences were determined using analysis of variance, and Dunnett’s or Bonferroni post t-tests,
as appropriate.
Results: The positive control, resveratrol (24 h), significantly enhanced cholesterol efflux to apoA-I at concentrations
≥30 μM. By contrast, cholesterol efflux to apoA-I was significantly inhibited by nigericin (45%; p<0.01) and
oligomycin (55%; p<0.01), under conditions (10 μM, 3 h) which did not induce cellular toxicity or deplete total
cellular ATP content. Levels of ATP binding cassette transporter A1 (ABCA1) protein were repressed by oligomycin
under optimal efflux conditions, despite paradoxical increases in Abca1 mRNA. Oligomycin treatment did not affect
cholesterol biosynthesis, but significantly inhibited cholesterol esterification following exposure to acetylated LDL,
and induced apoptosis at ≥30 μM. Finally, oligomycin induced the expression of genes implicated in both
cholesterol efflux (Abca1, Abcg4, Stard1) and cholesterol biosynthesis (Hmgr, Mvk, Scap, Srebf2), indicating
profound dysregulation of cholesterol homeostasis.
Conclusions: Acute loss of mitochondrial function, and in particular Δψm, reduces cholesterol efflux to apoA-I and
dysregulates macrophage cholesterol homeostasis mechanisms. Bioavailable antioxidants, targeted to mitochondria
and capable of sustaining effective mitochondrial function, may therefore prove effective in maintenance of
arterial health.
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Atherosclerosis is associated with increased production of
reactive oxygen species (ROS) in mitochondria, accumula-
tion of mitochondrial DNA damage, and progressive re-
spiratory chain dysfunction [1-4]. In turn, mitochondrial
dysfunction is induced by hypercholesterolemia, hypergly-
cemia, hypertriglyceridemia, and even the process of
aging. Increased oxidative stress within the artery wall
modifies low-density lipoprotein (LDL) to a form recog-
nised by macrophage scavenger receptors, resulting in the
unregulated uptake of excess cholesterol and cholesteryl
esters within macrophage ‘foam cells’, a hallmark of early
and developing atheroma [1-5].
Regression and stabilisation of atherosclerotic lesions
requires the efficient removal of cholesterol from macro-
phage ‘foam cells’ to apolipoprotein (apo)A-I or apoE,
allowing nascent high density lipoprotein (HDL) parti-
cles to enter and mature within the reverse cholesterol
transport (RCT) pathway in the bloodstream, which deli-
vers excess cholesterol to the liver for excretion as bile
and bile acids [6]. Recently, we demonstrated that mito-
chondrial cholesterol transport is a key step controlling
macrophage cholesterol efflux, the first step in the RCT
pathway [7]. Notably, overexpression of steroidogenic
acute regulatory protein (StAR; StarD1) in macrophages
increases delivery of cholesterol to sterol 27-hydroxylase
(CYP27A1), located on the inner mitochondrial mem-
brane [7]. Sterol 27-hydroxylase generates oxysterol
ligands for Liver X Receptors (LXRα/β); nuclear transcrip-
tion factors which act as master regulators of genes en-
coding proteins involved in the cholesterol efflux pathway
[8]. These include ATP binding cassette (ABC) transpor-
ters, such as ABCA1 and ABCG1/ABCG4, which work in
concert to transfer cholesterol across the plasma mem-
brane to apoA-I and HDL, respectively [9,10].
High levels of sterol 27-hydroxylase are found to co-
localise with macrophages in human atherosclerotic
lesions [11], and 27-hydroxycholesterol is a major oxy-
sterol in human atheroma [12]. The importance of
CYP27A1 in macrophage cholesterol homeostasis is high-
lighted by the rare genetic disorder, cerebrotendinous
xanthomasis, which is characterized by increased risk of
premature atherosclerosis, despite normal concentra-
tions of cholesterol in the bloodstream [13]. Importantly,
the rate-limiting step controlling the activity of sterol 27-
hydroxylase is the supply of cholesterol to the enzyme,
which can be mediated by the interaction of StAR with a
protein complex located at contact sites between outer
and inner mitochondrial membranes [7,14-16].
These findings, together with studies on mitochondrial
cholesterol transport in steroidogenic tissues [16-19] led
directly to our original hypothesis: that mitochondrial
function be intrinsically linked to efficiency of macro-
phage cholesterol efflux, with consequences for othercholesterol homeostasis mechanisms. Certainly, transfer
of cholesterol from the outer to the inner mitochondrial
membrane requires energised, polarised and actively re-
spiring mitochondria [16-20], while compounds such as
resveratrol (3, 4’, -5-trihydroxy-trans-stilbene), which
protect mitochondrial function by inducing mitochon-
drial biogenesis [21] and reducing oxidative stress [22],
are also reported to increase macrophage cholesterol ef-
flux [22-24]. However, resveratrol is also reported to in-
duce the expression of LXRα [23] and to impact
positively on cholesterol flux in human cells via PPAR γ
and adenosine [24], suggesting pleiotropic modes of ac-
tion for this molecule.
The aim of this study was to use established and spe-
cific modulators of mitochondrial function (antimycin,
dinitrophenol, nigericin and oligomycin) to test whether
a causal link exists between loss of mitochondrial func-
tion and impaired macrophage cholesterol efflux.
Changes in cell viability and cytotoxicity, membrane po-
tential and total ATP levels were compared with the
ability of macrophages to efflux cholesterol to apoA-I;
resveratrol was included as a putative positive control in
these experiments, as this molecule is known to exert
hormetic and cell-specific effects [25]. The results have
implications for diseases associated with impaired mito-
chondrial function, including ageing, atherosclerosis,
Alzheimer’s disease and diabetes.
Results
The first part of this study set out to confirm the
reported positive impact of resveratrol on cholesterol ef-
flux, in particular under conditions of demonstrably un-
impaired (or improved) mitochondrial function and
sustained cellular viability [21-24]. The impact of resver-
atrol (0-100 μM; 24 h) on the conversion of MTT to for-
mazan is shown in Figure 1A, with a significant decline
in cell viability noted at 100 μM. Concentrations of
50 μM (p<0.01) and 100 μM (p<0.001) were associated
with significantly increased release of cytosolic LDH into
the medium (Figure 1B), and decreased Caspase 3/7 ac-
tivity (p<0.05) (Figure 1C), suggesting cellular necrosis,
rather than induction of apoptosis. Levels of ATP
showed a similar pattern of decline, with a significant
58% reduction (p<0.001) noted at 100 μM resveratrol
(Figure 1D). Interestingly, despite the proposed functions
of resveratrol [21-24], this compound impacted nega-
tively on membrane potential, with minor but reprodu-
cible losses noted at concentrations ≥30 μM (Figure 1E),
concentrations used previously to demonstrate cardio-
protective properties for this compound [23]. As previ-
ously described [22], resveratrol significantly increased
the efflux of [3H]cholesterol (Figure 1F) to apoA-I
(20 μg ml-1), but only at the limit of this concentration












Figure 1 The effect of resveratrol, used at the concentrations indicated for 24 h on A) cell viability, B) cytotoxicity, C) apoptosis, D)
total cellular ATP levels, E) mitochondrial membrane potential, and F) efflux of [3H]cholesterol to apoA-I (20μg ml-1), as described in
the Methods. Values are the mean±SEM of between three to four independent experiments; *p<0.05; **p<0.01 and ***p<0.001 compared with
control macrophages.
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cAMP [20]). These findings therefore provide only lim-
ited evidence for a positive impact of this ‘nutriceutical’
on macrophage cholesterol efflux, suggesting that other
properties of this compound may be more important in
conferring cardioprotection [21-24].
The second part of this study therefore sought evidence
that loss of mitochondrial function diminishes the athero-
protective cholesterol efflux pathway, again under condi-
tions without overt loss of cell viability, release of cytosolic
LDH or loss of total cellular ATP; reductions in mitochon-
drial membrane potential were, however, predicted for
some compounds by previous studies [16-19,26], and
formed part of the hypothesis under test. Mitochondrial
inhibitors, nigericin and antimycin, decreased cellular via-
bility (Figure 2A) and/or tended to increase release of cyto-
solic LDH into the medium (Figure 2B) at concentrations ≥
30 μM after 3 h, while dinitrophenol or oligomycin had no
significant impact on either parameter during this period.
By contrast, more prolonged incubation (24 h) with these
inhibitors caused substantive loss of cell viability, with esti-
mated LD50 values of 1 μM (antimycin), 75 μM (dinitrophe-
nol), 1 μM (nigericin) and 8 μM (oligomycin), as judged by
MTT conversion to formazan (data not shown). During a
3 h incubation, intracellular levels of ATP were depleted by
oligomycin (30 μM) and nigericin (≥10 μM) by 24%
(p<0.01) and 28% (p<0.001), respectively, but not by theother drugs tested (Figure 2C), while mitochondrial mem-
brane potential declined significantly by 39% (p<0.05) only
in the presence of oligomycin (≥10μM).
When tested at concentrations which did not affect cel-
lular viability (10 μM; 3 h), only nigericin and oligomycin
inhibited efflux of [3H] cholesterol to apoA-I (Figure 3A)
by 45% (p<0.01) and 55% (p<0.01), respectively, following
preincubation with dibutyryl cAMP (0.3 mM). By con-
trast, neither antimycin nor dinitrophenol significantly
changed cholesterol efflux to apoA-I. While macrophage
levels of ABCA1 protein were modestly increased follow-
ing oligomycin treatment, levels of this protein were
repressed by oligomycin (34±17%; n=3; p<0.05) in macro-
phages incubated under optimal efflux conditions
(0.3 mM dibutyryl cAMP and 20μg ml-1 apoA-I), and by
comparison with GADPH (Figure 3B).
Oligomycin treatment induced gene expression of
Abca1 and Abcg4 mRNA, together with genes encoding
other enzymes and transcription factors involved in
cholesterol metabolism, including Hmgcr, Mvk, Scap1,
Srebf1, Srebf2 and Stard1 (Figure 4A). Further, when
macrophages were incubated in the presence of acety-
lated LDL (50 μg ml-1) to induce ‘foam cell’ formation,
oligomycin (10 μM; 3 h) inhibited acyl CoA: cholesterol
acyltransferase (ACAT1) activity by 35% (p<0.01), as
judged by incorporation of [3H]oleate (10 μM) into the










































































Lane 1: Control cells 
Lane 2: Dibutyryl cAMP (0.3mM; 24h) followed by treatment with apoA1 
(20µg/ml-1; 3h)
Lane 3: Oligomycin (10µM; 3h), 
Lane 4: Dibutyryl cAMP (0.3mM; 24h) followed by treatment with 
1 2 3 4
A B
oligomycin (10  M) and apoA1 (20  g ml-1) for 3h.   
Figure 3 The effects of mitochondrial inhibitors, antimycin, dinitrophenol, nigericin and oligomycin, each used at 10μM for 3 h, on
efflux of [3H]cholesterol to apoA-I (20 μg ml-1) is shown in Figure 3A. Where indicated, macrophages were preincubated for 24 h in the
presence of dibutyryl cAMP (0.3 mM) to induce expression of ABCA1 and cholesterol efflux [25]. Values are the mean ± SEM of between four to
six independent experiments; **p<0.01 compared with control macrophages; other significant changes are indicated on the figure. Expression of
ABCA1 protein under the conditions noted is shown in Figure 3B; values are shown relative to the housekeeping gene, GAPDH, and are













Figure 2 The effects of mitochondrial inhibitors, antimycin, dinitrophenol, nigericin and oligomycin, used at the concentrations
indicated for 3 h on A) cell viability, B) cytotoxicity, C) total cellular ATP levels and D) mitochondrial membrane potential, as described
in the Methods. Values are the mean±SEM of between three to four independent experiments; *p<0.05; **p<0.01 and ***p<0.001 compared
with control macrophages.





































































































































































Figure 4 The effect of oligomycin (10 μM; 3 h) on A) fold-change of genes involved in cholesterol metabolism and lipoprotein
signalling in RAW 264.7 macrophages, compared with control cells, as judged by Q-PCR analysis of genes implicated in the cholesterol
efflux, biosynthesis and esterification pathways; B) incorporation of [3H]oleate (10 μM) into the cholesteryl ester pool, measured in the
presence of absence of acetylated LDL (50 μg ml-1; 3 h); C) incorporation of [14C]acetate into free cholesterol, cholesteryl ester, fatty
acids, phospholipids and triacylglycerol (3 h) and D) induction of apoptosis in RAW 264.7 murine macrophages. Values are the mean
±SEM of between three to six independent experiments. *p<0.05, **p<0.01 and ***p<0.001 compared with control macrophages.
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incorporation of [14C]acetate into cholesteryl ester, fatty
acid and phospholipid pools, while biosynthesis of free
[14C]cholesterol remained unaffected (Figure 4C). Finally,
increasing concentrations of oligomycin were associated
with a trend towards increasing macrophage apoptosis
(Figure 4D), which proved significant at 30 μM.Discussion
Loss of mitochondrial function, a key element of athero-
genesis, is caused by an increase in reactive oxygen spe-
cies, resulting in accumulation of mitochondrial DNA
damage, and respiratory chain deficiencies, apoptosis
and cell death, favouring plaque formation and instabil-
ity [1-5]. This study argues that dysregulation of macro-
phage cholesterol homeostasis should also join this list,
apparently driven by the specific loss of macrophage
cholesterol efflux to apoA-I.Notably, resveratrol, a natural phytoalexin antioxidant
found in grapes and red wine, known to induce mitochon-
drial biogenesis and protect against atherosclerosis in ani-
mal models [23,25], increased cholesterol efflux to apoA-I,
at concentrations around 20-30 μM, as previously
described [22,24]. However, it is evident that concentra-
tions of resveratrol (30-100 μM) which increase choles-
terol efflux (Figure 1), and indeed those reported to
activate LXRα [23], are associated with loss of mitochon-
drial membrane potential and cell viability and induction
of cytotoxicity in RAW 264.7 macrophages. Moreover,
since resveratrol is characterised by high absorption but
very low bioavailability, coupled with extensive and rapid
metabolism to conjugates of this compound [27], it seems
unlikely that monocyte-macrophages would be exposed to
the concentrations of resveratrol needed to stimulate the
cholesterol efflux process. For example, absorption (70%)
of a dietary relevant 25 mg oral dose generated peak
plasma levels of around 2 μM resveratrol metabolites, with
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the plasma (<5 ng ml-1) [27]. However, it may be possible
that the more potent antioxidant function of resveratrol
(≤5 μM) [22], or the ability of this compound to amplify
SIRT-1 dependent biogenesis of mitochondria (≤10 μM)
[21], might help to sustain mitochondrial function in vivo,
particularly if local depots of resveratrol accumulate
within arterial cells. If so, macrophages may have to be
oxidatively challenged, or subject to chronic incubation
with resveratrol, for the protective impact of this com-
pound on the cholesterol efflux pathway to become more
(patho)physiologically relevant.
By contrast, inhibitors of differing aspects of mitochon-
drial function (ΔpH, Δψm complex III or complex V)
exerted convincing, if selective, effects on the cholesterol
efflux pathway over the acute time period tested here.
Notably, the uncoupling agent, dinitrophenol, and com-
plex III inhibitor, antimycin, had negligible impact on ef-
flux to apoA-I, while nigericin and oligomycin both
reduced efflux to apoA-I. While nigericin (10 μM)
decreased total cellular ATP levels, which could impact on
the activity of ABC transporters, ABCA1 and ABCG1/G4,
oligomycin did not alter cell viability or total ATP levels,
but did significantly reduce Δψm, unlike the other inhibi-
tors tested. In turn, loss of Δψm due to oligomycin was
associated with inhibition of cholesterol esterification and
a trend towards induction of apoptosis, together with
increased expression of an array of genes involved in chol-
esterol homestasis, arguing a profound dysregulation of
cholesterol homeostasis as sequelae of acute loss of mito-
chondrial function. Importantly, the coordinated response
which should link impaired cholesterol efflux with
SREBP-2 repression of cholesterol biosynthesis and LDL
uptake, and with increased cholesterol esterification,
seems to be lost.
While this is the first study to focus on the importance
of mitochondria in regulation of macrophage cholesterol
efflux, related studies have been performed in steroido-
genic cells [16–19; 26]. As previously introduced, the
rate-limiting step in the generation of steroid hormones,
is the transfer of cholesterol into mitochondria, to the
CYP11A1 protein which resides on the inner mitochon-
drial membrane. Dissipation of Δψmwith CCCP, inhib-
ition of electron transport using antimycin A, disruption
of pH using nigericin, and inhibition of F0/F1 ATP syn-
thase using oligomycin, all inhibited progesterone syn-
thesis in Leydig cells, indicating that altered
mitochondrial function regulates steroid biosynthesis
[16–19; 26]. However, in RAW 264.7 macrophages, only
nigericin and oligomycin regulated macrophage choles-
terol efflux to apoA-I, and at concentrations 10-fold
higher than those required to inhibit steroidogenesis
[16-19,26]. It is noteworthy that cellular ATP content
was more sensitive to depletion by mitochondrialdisruption in Leydig cells than in RAW 264.7 macro-
phages, as only oligomycin (≥30 μM) and nigericin
(≥10 μM) reduced cellular ATP levels over the same
time scale in the latter; equally, Δψm was markedly
reduced by antimycin (1 μM) and oligomycin (1 μM) in
Leydig cells, while only oligomycin (≥10 μM) affected
this parameter in the current study. This may explain
the apparent selectivity for nigericin and oligomycin in
repression of cholesterol efflux to apoA-I; certainly, loss
of either Δψm or cellular ATP seems sufficient to nega-
tively affect macrophage cholesterol efflux when cell via-
bility is sustained (Figures 2 and 3).
Oligomycin treatment, by limiting cholesterol efflux
(Figure 2A) and reducing cholesterol esterification
(Figure 4B), without impacting on cholesterol biosyn-
thesis (Figure 4C), should therefore lead to accumulation
of sterol at the endoplasmic reticulum (ER). This should
trigger a protective cholesterol homeostasis response,
sequestering SREBPs at the ER, and providing oxysterol
ligands for Liver X Receptors (LXRs) complexed with
retinoid X receptors (RXR) at the LXR response element
within genes involved in the cholesterol efflux pathway
[8]. Sterol-dependent sequestration of SREBPs at the ER
prevents proteolytic processing of this transcription fac-
tor to the nuclear SREBP fragment capable of inducing
the transactivation of genes involved in cholesterol bio-
synthesis and uptake. However, instead of these correctly
orchestrated events, treatment with oligomycin resulted
in upregulation of genes involved in both cholesterol
biosynthesis (Hmgr, Mvk, Scap, Srebf1, Srebf2) and efflux
(Abca1, Abcg4, StarD1) pathways, arguing a profound
dysregulation of this response. The mechanism involved
was not investigated here, but it is possible to speculate
that loss of mitochondrial production of oxysterol LXR
ligands [7] may release SREBP2 from the ER, explaining
the increased expression of genes involved in increasing
cholesterol biosynthesis. This could then result in
increased production of 24(S),25-epoxycholesterol via
the cholesterol biosynthetic pathway [28], facilitating
LXR activation and induction of genes involved in the
efflux process.
One further outcome predicted by the macrophage
lipid phenotype observed following oligomycin treat-
ment is toxic overaccumulation of cholesterol at the ER,
which can trigger oxidative stress and proteasomal deg-
radation of existing ABCA1 protein [29] and ultimately
trigger apoptosis, observed at higher concentrations of
oligomycin (Figure 4D). While it is clear that oligomycin
induction of Abca1 mRNA may explain the modest in-
crease in ABCA1 protein under basal conditions, a clear
reduction in ABCA1 is noted when macrophages are
treated with this inhibitor under optimal efflux condi-
tions (Figure 3B), which agrees well with the observed
loss of [3H]cholesterol efflux to apoA-I under this
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sion of ABCA1 mRNA and protein in oligomycin-
treated macrophages under this condition reflects that
observed in carotid atherosclerotic lesions, where ele-
vated Abca1 mRNA is associated with reduced expres-
sion of ABCA1 protein [30].Conclusions
Loss of mitochondrial function impacts negatively on
macrophage cholesterol homeostasis, reducing efflux to
apoA-I and impairing cholesterol esterification, events
which may trigger accumulation of toxic free cholesterol
and induction of apoptosis within arterial macrophages,
contributing to lesion development. Small drug mole-
cules, specifically targeted to accumulate within the
mitochondria [31] and capable of sustaining Δψm might,
therefore, not only reduce arterial oxidative stress, but
also improve cholesterol homeostasis and efflux from
macrophage ‘foam’ cells, regressing and stabilising ath-
erosclerotic plaque.Methods
Materials
Murine RAW 264.7 macrophages were purchased from
the European Collection of Cell Cultures (ECACC;
Health Protection Agency Culture Collection, Porton
Down, UK). Tissue culture reagents were purchased
from Lonza (Wokingham, UK); other sources include
FuGene6 transfection reagent (Roche), NuPAGE gels
and buffers (InVitrogen), antibodies (AbCAM, Cam-
bridge, UK), primers and probes (Eurogentec, Belgium).
Athens Research (USA) provided apoA-I and low density
lipoprotein (LDL); LDL was acetylated according to
Brown et al. [32]. Radiolabels ([3H]cholesterol and [14C]
acetic acid) were provided by ICN Biologicals; all other
chemicals were provided by Sigma-Aldrich (Poole, Dor-
set, UK).Cell Culture
Murine RAW 264.7 macrophages were sustained using a
split ratio of 1:4, in Dulbecco’s Modified Eagles Medium
(DMEM) supplemented with foetal bovine serum (FBS,
10%, v/v), L-glutamine (200 mM) and penicillin/strepto-
mycin (50 μg ml-1; 50 U ml-1, respectively). For experi-
ments, cells were plated onto 12-well tissue culture
dishes at an initial density of 0.5x106 cells well-1, under
serum-free conditions, except where stated. Compounds
with an established role in modulation of mitochondrial
function (resveratrol, antimycin, dinitrophenol, nigericin
and oligomycin) were added using DMSO (<0.01%) as
vehicle, at the concentrations and time periods indicated
in the Legends to Figures.Macrophage lipid analysis and cholesterol efflux
Incorporation of [14C]acetic acid (1 μCi ml-1) into fatty
acid, phospholipid, cholesterol, cholesteryl ester and tria-
cylglycerol pools were measured after incubation for 3 h
in the presence of oligomycin (10 μM), as previously
described [7,33]. Esterification of cholesterol, in the pres-
ence of acetylated LDL (50 μg ml-1) was monitored by
flux of [3H]oleic acid (10 μM; 1 μCi ml-1) into choles-
teryl [3H]oleate, as previously [33]. Macrophage lipids
were extracted using hexane:isopropanol (3:2, v/v) and
dried under nitrogen, before separation by t.l.c. using
chloroform, methanol and water (60:30:5, by vol.) as the
first mobile phase, and hexane, diethyl ether and acetic
acid (80:20:1.5, by vol.) in the second phase of develop-
ment; lipids were identified by co-migration with au-
thentic standards [7,33].
Macrophage efflux of [3H]cholesterol to apoA-I and
HDL were determined as previously described [7,33]. Ef-
flux from radiolabelled macrophages, was initiated by
addition of serum-free DMEM containing human apoA-
I (20 μg ml-1) or HDL (20 μg ml-1) for 3 h; preincubation
(24 h) with dibutyryl cAMP (0.3 mM) is required in this
cell line to induce ABCA1, as previously described [20].
Results are expressed as % cholesterol efflux, calculated
as [dpm(media)/dpm(media+cells)] x 100%.
Analysis of mRNA and protein expression
Total RNA was isolated (TriZol) from macrophages, and
reverse transcribed in cDNA (BioLine) prior to measure-
ment of cellular levels of Abca1, Ldlr, Mvk, Nr1h3, Scap,
Soat1, Srebf1 and Srebf2 by quantitative polymerase
chain reaction (Q-PCR), relative to Gapdh, using pri-
mers and fluorescent (FAM/TAMRA) probe sequences,
and protocols cited in [7]. Levels of Abcg4 were deter-




Macrophage cell lysates were prepared in RIPA
buffer (25 mM Tris HCl pH7.6, 150 mM NaCl, 1% (v/v)
NP-40, 1% (w/v) sodium deoxycholate, 0.1% (w/v) so-
dium dodecyl sulphate) supplemented with CompleteTM
protease inhibitor cocktail (Roche), and proteins
(50 μg lane-1) separated by SDS PAGE (NuPAGE;
10% gels), transferred to a PDVF membrane and
probed using anti-ABCA1 (1:1000) and anti-GAPDH
(1:2000) rabbit polyclonal antibodies, and detection
achieved using secondary antibodies coupled to the
ECL detection system [7,33].
Assessment of macrophage viability, apoptosis and
mitochondrial function
Cell viability was assessed by conversion of methyl thiazo-
lyl blue tetrazolium bromide to formazan, via succinate:
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and by release of lactate dehydrogenase into the medium
(LDH Cytotoxicity Assay Kit, Cambridge Biosciences).
Membrane potential was assessed by tetramethylrhoda-
mine fluorescence [17], total cellular ATP using the luci-
ferase Celltiter Glo-Bioluminescent reagent supplied by
Promega, and apoptosis by monitoring Caspase 3/7 activ-
ity (Promega).
All values indicate mean±S.E.M., with numbers of in-
dependent experiments denoted by n. Significant
(p<0.05) differences were determined using analysis of
variance and Dunnett’s, or Bonferroni post t-tests, as
appropriate.
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